Maravai LifeSciences (MRVI) vs Zymeworks (ZYME)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Maravai LifeSciences (MRVI) has outperformed Zymeworks (ZYME) over the past year, gaining 124.5% versus a gain of 60.8%. Over five years, ZYME leads with a +2.3% price change compared with -80.0% for MRVI. Maravai LifeSciences is the larger company by market cap ($2.75 billion vs $1.90 billion), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MRVI | ZYME |
|---|---|---|
| Share price | $7.43 | $26.53 |
| Market cap | $2.75B | $1.90B |
| 1-day change | -5.35% | +3.43% |
| YTD return | +128.62% | +0.76% |
| 1-year return | +124.47% | +60.79% |
| 5-year return | -79.97% | +2.27% |
| Forward P/E | — | 30.43 |
| EPS (TTM) | $-0.53 | $-2.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.42 | $31.34 |
| 52-week low | $2.55 | $16.00 |
| Distance from 52-week high | -21.13% | -15.35% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +5.38% | +55.33% |
| Average volume | 3.30M | 676.63K |
| Shares outstanding | 148.99M | 71.20M |
| Employees | 415 | 231 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MRVI has outperformed ZYME by 63.7 percentage points over the past year.
About Maravai LifeSciences
MRVI stock →Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS.
Health Care · Biotechnology: Pharmaceutical Preparations · 415 employees
About Zymeworks
ZYME stock →Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees
MRVI vs ZYME FAQ
Which is bigger, Maravai LifeSciences or Zymeworks?
Maravai LifeSciences (MRVI) is larger, with a market capitalization of $2.75B compared with $1.90B for Zymeworks (ZYME).
Which stock has performed better over the past year, MRVI or ZYME?
MRVI returned +124.47% over the past 12 months, compared with +60.79% for ZYME (price return, excluding dividends). Past performance does not predict future results.
Are Maravai LifeSciences and Zymeworks in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.